Sharemaestro Newsreel

Zhengye’s closing bid price met Nasdaq’s $1 floor for 10 business days

Lifecore Biomedical Releases Q2 2026 Financial Results

Lifecore Biomedical, Inc. (LFCR) reported its Q2 2026 financial results, narrowing its loss per share to -$0.19 and exceeding revenue expectations with $34.2 million. Despite beating estimates, the company experienced a 6.2% revenue decline year-over-year due to softness in its CDMO segment. Management provided …

Liquidia (NASDAQ:LQDA) Reaches New 1-Year High - Here's Why

Liquidia (NASDAQ:LQDA) reached a new 52-week high of $91.36, closing up 1.6% at $90.87, driven by positive analyst sentiment and strong quarterly earnings, where revenue surged over 4,000%. Despite this, company insiders sold approximately 2.18 million shares worth $143.9 million in the last 90 …

Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Lifecore Biomedical (NASDAQ:LFCR) reported its quarterly earnings, exceeding analyst estimates with an EPS loss of $0.19, $0.03 better than expected, and revenue of $34.17 million, surpassing the $32.02 million forecast. Despite a year-to-date revenue decline and widened net loss, the company reaffirmed its 2026 …

United Therapeutics (UTHR) Stock Flat As Profit Strength Meets Revenue Doubts

Evolus, Inc. Q2 2026: Revenue $84.08M, EPS ($0.12) — 10-Q Summary

Evolus, Inc. reported its Q2 2026 financial results, with revenue increasing to $84.08 million from $69.39 million in the prior year quarter, marking a 21.2% year-over-year growth. The company also narrowed its net loss, reporting a diluted EPS of ($0.12) compared to ($0.27) a …

Elanco Animal Health (ELAN) Stock Eyes Margin Momentum As Debt Questions Linger

Elanco Animal Health's stock rose 2.4% following its Q2 2026 report, which showed significant improvement in adjusted EBITDA and gross margin, despite trailing losses. The company's "Big 6" portfolio and new products like Zenrelia and Credelio Quattro are driving revenue growth and market penetration. …

HIMS & HERS HEALTH, INC. INVESTOR ALERT: Kirby McInerney

Kirby McInerney LLP has announced an investigation into potential securities fraud against Hims & Hers Health, Inc. following a lawsuit filed by the Federal Trade Commission (FTC). The FTC accused Hims of sharing customers’ medical information with third-party advertisers, specifically Meta Platforms, leading to …

Alpha Teknova (Nasdaq: TKNO) raises 2026 guidance after Q2 growth

Alpha Teknova (Nasdaq: TKNO) reported strong Q2 2026 financial results, with revenue increasing 18% to $12.2 million and improved profitability metrics. Following this performance, the company raised its 2026 revenue guidance to $45-$47 million and lowered its Free Cash Outflow expectations to less than …

Zacks Investment Ideas feature highlights: Lenovo, Victoria's Secret and Liquidia

Zacks Investment Ideas highlights three top-ranked stocks: Lenovo Group, Victoria's Secret, and Liquidia Corp., all showing strong earnings momentum and positive price action. Lenovo is transforming into an AI hardware provider with significant revenue growth, Victoria's Secret is undergoing a successful brand turnaround with …

Aurora Cannabis (TSX:ACB) Stock Chases Medical Growth While Cash Flow Lags

Eton Pharmaceuticals Promotes Radosavljevic to Chief Operating Officer

Eton Pharmaceuticals has promoted Danka Radosavljevic to Chief Operating Officer, recognizing her five years of service as Executive Vice President, Operations. Her new role includes an annual base salary of $520,800 and a discretionary incentive bonus, formalizing her expanded authority over daily operations and …

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals has acquired the U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals, a late-stage product candidate for the treatment of proliferating superficial infantile hemangiomas. This acquisition complements Eton's existing product HEMANGEOL®, aiming to address a broader spectrum of infantile hemangioma patients, …

Eton Pharmaceuticals licenses ASN-001 for infantile hemangiomas

Eton Pharmaceuticals (NASDAQ: ETON) has licensed U.S. rights to ASN-001, a timolol topical gel for treating infantile hemangiomas, from Auson Pharmaceuticals. The company plans to submit a New Drug Application in the second half of 2027 following positive Phase II/III trial results showing significant …

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics, Inc. to discover new treatments for autoimmune and inflammatory diseases. The partnership will leverage Evotec's AI-enabled discovery platform and advanced screening capabilities with Odyssey's disease biology expertise to accelerate the identification of drug candidates. …

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue reaching $218.3 million and ORLADEYO net revenue at $158.2 million, leading to an operating profit of $98.5 million. The company maintained its full-year ORLADEYO revenue guidance and increased total revenue guidance, while …

Phibro Animal Health (PAHC) HR chief sells 265 shares to cover tax withholding

Lisa Ann Escudero, SVP of Human Resources at Phibro Animal Health (PAHC), sold 265 shares of Class A Common Stock on August 4, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units. The transaction was a broker-assisted cashless sale …

Elanco Animal Health posts Q2 2026 revenue $1.37B, raises full‑year guidance and improves net leverage

Elanco Animal Health reported strong second-quarter 2026 results, achieving $1.368 billion in revenue, a 10% year-over-year increase, and raising its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS. The company also improved its year-end net leverage target and saw significant contributions from products …

Aurora Cannabis Inc (ACB) (Q1 2027) Earnings Call Highlights: International Strength Drives ...

Aurora Cannabis Inc. reported Q1 fiscal 2027 net revenue of CAD67.6 million, largely driven by a 17% increase in international medical cannabis revenue, especially from Germany. Despite a strong adjusted gross margin of 58% and a robust balance sheet with nearly CAD150 million in …

$Zhengye Biotechnology (ZYBT.US)$ Will there be another miracle?[Grin][Cool Guy]

The article poses a question about whether Zhengye Biotechnology (ZYBT.US) will experience another "miracle." It's a brief post from a user named "活的踏实 活的精彩" within the moomoo Community, indicating a discussion about the stock's future performance. The post itself is minimal, serving primarily as …

Earnings call transcript: Akebia Therapeutics posts mixed Q2 2026 results as stock falls

Akebia Therapeutics reported its second-quarter earnings, highlighting significant revenue growth for its Vafseo anemia treatment and positive interim results from the VOICE study, which met its stopping criteria for non-inferiority and superiority. The company also detailed advancements in its rare kidney disease pipeline with …

Earnings call transcript: Evolus tops revenue forecast in Q2 2026, shares rise

Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict

Takeda Pharmaceuticals is arguing that an $885 million antitrust verdict against it, related to delaying generic competition for its IBS drug Amitiza, should be reduced. The drugmaker contends that rebates it paid and Medicare subsidies received by health plans should be factored into the …

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2

Evolus, Inc. (EOLS) reported break-even quarterly earnings per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $0.01 loss and significantly improving from a $0.24 loss a year ago. The company also exceeded revenue expectations, posting $84.08 million against an estimated $82.02 …

Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...

Supernus Pharmaceuticals Inc (SUPN) reported strong revenue growth in Q2 2026, driven by key product sales and advancements in its late-stage pipeline. Despite competitive pressures and increased R&D expenses, the company reaffirmed its full-year financial guidance, projecting net revenue between $640 million and $660 …

US FDA approves Takeda's sleep disorder pill

The U.S. Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals' oral drug, Orzeyful, for narcolepsy, making it the first treatment to target all symptoms of the rare sleep disorder. Orzeyful works by directly addressing the loss of orexin signaling, which is the cause …

Pacira BioSciences (PCRX) Stock Stumbles As Margin Erosion Clouds Profit Return

Earnings call transcript: Aurora Cannabis Q1 2027 profit falls as global sales grow

Aurora Cannabis reported a decline in Q1 2027 adjusted EBITDA and negative free cash flow, despite a 17% increase in international medical cannabis revenue, which now accounts for 64% of total net revenue. The company is strategically shifting focus to higher-margin international medical cannabis …

Earnings Flash (ACB) Aurora Cannabis Inc. Reports Q1 Revenue C$67.6M, Vs. FactSet Est of C$67.4M

Aurora Cannabis Inc. (ACB) announced its Q1 revenue reached C$67.6 million, surpassing the FactSet estimate of C$67.4 million. This indicates a slight beat on analyst expectations for the quarter.

Is Emergent BioSolutions Inc (EBS) Overvalued After Q2 Earnings

Earnings call transcript: Teknova posts record Q2 2026 revenue and raises outlook

Teknova (TKNO) reported record Q2 2026 revenue of $12.2 million and a narrower-than-expected loss of $0.06 per share, leading the company to raise its full-year 2026 revenue guidance to $45-$47 million. Despite the strong financial performance and the launch of an AI-powered custom order …

Zhengye Biotechnology Company Profile & Introduction

This document appears to be a company profile and introduction for Zhengye Biotechnology. Without further content, a detailed summary is not possible, but it likely outlines the company's operations, mission, and key offerings within the biotechnology sector.

BioAge Labs (NASDAQ:BIOA) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock

Kevin Mcculloch, an insider at Xeris Biopharma (NASDAQ:XERS), sold 15,000 shares of the company's stock for $120,300 on August 3rd, reducing his total holdings by 0.89%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. The company's stock has shown positive performance, …

United Therapeutics (UTHR) lifts Q2 EPS, details $2.0B share buyback plan

United Therapeutics reported Q2 2026 financial results, with net income rising to $333.0 million and diluted EPS to $7.27, despite a 2% decrease in total revenues to $783.3 million. The company announced a $2.0 billion share repurchase program, including $1.5 billion in accelerated repurchases, …

Akebia Ther earnings beat by $0.01, revenue fell short of estimates